Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.
about
Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantationTacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantationAMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agentComparison of pooled risk estimates for adverse effects from different observational study designs: methodological overviewCurrent and future approaches for control of graft-versus-host disease.Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.Pathogenesis and management of graft-versus-host disease.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventStem cells and regenerative medicine: accomplishments to date and future promise.Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigmaHarvesting, processing and inventory management of peripheral blood stem cellsAlterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complicationsAre predictive factors clinically useful in bone marrow transplantation?Emerging therapies for graft-versus-host disease.Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CYNew approaches for preventing and treating chronic graft-versus-host disease.Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrowAcute graft versus host disease.Recent advances in the treatment of graft-versus-host disease.Overview of T-cell depletion in haploidentical stem cell transplantation.Dendritic cells in allogeneic hematopoietic stem cell transplantation.Prevention of graft-vs.-host diseaseOcular graft versus host disease in allogenic haematopoetic stem cell transplantation in a tertiary care centre in India.Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Ocular manifestations of graft-versus-host disease
P2860
Q24235827-5279F6F5-5C38-4DB4-BA21-997D2ECC8130Q26472072-AAB2DFE3-EABB-4F59-870F-2A5588791552Q28286940-F4CAC153-607B-4F62-851F-E9A61ACC529AQ28535464-303744B9-E8EF-42A7-892F-FE13353CDCE5Q33642625-BD20971B-9FE7-403D-AB08-53ED090046DEQ33894784-9BBBE8FC-3CE3-4C31-B53E-1DBF498D393BQ33971524-C1225AB3-2669-4AE0-88D0-411D1DC8AD07Q34077479-71F7387E-5FE9-4E18-B178-51420F016B47Q34254787-D30E2318-F395-4416-8002-30BB06377A5EQ34343825-E106CE0A-0699-4D62-B64C-27F5A55B1015Q34369800-3A96E65F-6B4C-4D77-8F4C-140DF572B289Q34707280-1ECCA932-8EEE-4C83-B114-06CF5A447A4AQ35042830-38FBC18E-6C41-48A8-8001-CDC32C5EB746Q35078368-CFB7FE6D-3279-4CB3-849F-331142B0FEF4Q35083562-1810987A-E484-43C2-A422-AEBD3E04F8AFQ35084404-8739C4FB-819F-4183-A7BB-9EAC7F609C8CQ35199782-4C7264B0-1C9C-49D8-B0E1-FC452085618DQ35200663-A0D286DC-ADE9-4233-AE0F-76E3CC4A3282Q35561009-7AAB5418-7DD5-4457-9EF7-5EA3AA3224CAQ35602633-98FC9B4F-6E0C-45C7-A96C-A591A169B126Q35673530-5F228D35-2539-4030-91FB-431867B4C3E8Q35739130-D42A52F9-EF53-4982-80A6-1E936BE826C6Q35847596-542AD9A5-AF40-41B1-92FA-8383499DBF82Q35848787-251D35B8-E157-4322-9182-51EB87C93D43Q35849241-961726E9-357E-489C-8C7B-EB61DE9503C7Q35849351-675C3074-F305-4569-B3F2-C87DEBE8E3ABQ36059671-F6C2F458-B988-44A3-91A8-ED0598925CFEQ36148596-6678501D-91F0-417A-9354-D4188453FE09Q36159937-DDE33058-0876-4D2B-B755-E19474E6E403Q36272587-930E46DA-4F0E-4AAC-A1EB-6089BD7B0642Q36431047-F3133C2E-9863-4795-9AFC-2A0AC74107CEQ36550165-1E85FA2E-08E2-4261-898E-41BBF9145F6BQ36700499-56E3E9FA-D1A1-4A4E-9784-11A830573F14Q36945976-F2442C50-3298-4E12-A5AF-53D7E88876E5Q36980277-4543BF57-ACA1-4190-839A-1F92E8B1EE3AQ37041729-D500AB25-8D49-453D-8A6B-5667FE58ADD0Q37081469-2898FB73-5B54-4F96-91BA-9A6E464E274FQ37113099-29B53B0E-1E39-41E3-9D57-26B390F43321Q37144910-35872EEC-280B-4BC9-8629-094F10DDED36Q37163474-423AE7D3-DE7C-4FDB-98FD-F63DC8E6FF16
P2860
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@ast
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@en
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@nl
type
label
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@ast
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@en
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@nl
prefLabel
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@ast
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@en
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@nl
P2093
P1476
Acute and chronic graft-versus ...... nsplantation: a meta-analysis.
@en
P2093
P304
P356
10.1200/JCO.2001.19.16.3685
P407
P577
2001-08-01T00:00:00Z